Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression
Pablo Carabias, María V. Espelt, María L Bacigalupo, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 22

Showing 22 citing articles:

Targeting galectin-driven regulatory circuits in cancer and fibrosis
Karina V. Mariño, Alejandro J. Cagnoni, Diego O. Croci, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 4, pp. 295-316
Open Access | Times Cited: 137
Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
Fatemeh Davodabadi, Seyedeh Fatemeh Sajjadi, Mohammad Sarhadi, et al.
European Journal of Pharmacology (2023) Vol. 958, pp. 176013-176013
Closed Access | Times Cited: 55
Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects
Ya-ruo Lei, Xian-lu He, Jun Li, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 2, pp. 52-52
Open Access | Times Cited: 9
Advanced Generation Therapeutics: Biomimetic Nanodelivery System for Tumor Immunotherapy
Jie Li, Huamin Zeng, Luwei Li, et al.
ACS Nano (2023) Vol. 17, Iss. 24, pp. 24593-24618
Closed Access | Times Cited: 19
Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications
İlhan Yaylım, Melek Aru, Ammad Ahmad Farooqı, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 6
Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology
Nadia Bannoud, Juan C. Stupirski, Alejandro J. Cagnoni, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 3
Open Access | Times Cited: 13
ITGA5+synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis
Linli Zheng, Minghui Gu, Xiang Li, et al.
Annals of the Rheumatic Diseases (2024) Vol. 84, Iss. 2, pp. 232-252
Closed Access | Times Cited: 5
Inhibition of JNK/c-Jun-ATF2 Overcomes Cisplatin Resistance in Liver Cancer through down-Regulating Galectin-1
Fan Yang, Mengzhu Li, Duo Xu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 8, pp. 2366-2381
Open Access | Times Cited: 11
Study Models of Drug–Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels
Jéssica Veiga-Matos, Ana I. Morales, Marta Prieto, et al.
Molecules (2023) Vol. 28, Iss. 22, pp. 7532-7532
Open Access | Times Cited: 11
Engineered 3D liver-tissue model with minispheroids formed by a bioprinting process supported with in situ electrical stimulation
Won-Jin Kim, GeunHyung Kim
Bioactive Materials (2024) Vol. 35, pp. 382-400
Open Access | Times Cited: 4
A Bioinert Hydrogel Framework for Precision 3D Cell Cultures: Advancing Automated High‐Content and High‐Throughput Drug Screening
Hyunsu Jeon, Tiago Thomaz Migliati Zanon, James Carpenter, et al.
Small Science (2025)
Open Access
The multifaceted role of MUC1 in tumor therapy resistance
Weiqiu Jin, Mengwei Zhang, Changzi Dong, et al.
Clinical and Experimental Medicine (2022) Vol. 23, Iss. 5, pp. 1441-1474
Closed Access | Times Cited: 13
siRNA and targeted delivery systems in breast cancer therapy
Sepideh Mirzaei, Mahshid Deldar Abad Paskeh, Maliheh Entezari, et al.
Clinical & Translational Oncology (2022) Vol. 25, Iss. 5, pp. 1167-1188
Closed Access | Times Cited: 10
The interrelation of galectins and autophagy
Lujuan Zheng, Jing Xia, Pengyu Ge, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110336-110336
Closed Access | Times Cited: 5
The Blessed Union of Glycobiology and Immunology: A Marriage That Worked
Jhenifer Santos dos Reis, Israel Diniz-Lima, Marcos André Rodrigues da Costa Santos, et al.
Medicines (2023) Vol. 10, Iss. 2, pp. 15-15
Open Access | Times Cited: 4
Integrin α6β4 Confers Doxorubicin Resistance in Cancer Cells by Suppressing Caspase-3–Mediated Apoptosis: Involvement of N-Glycans on β4 Integrin Subunit
Yoshinobu Kariya, Jianguo Gu, Yukiko Kariya
Biomolecules (2023) Vol. 13, Iss. 12, pp. 1752-1752
Open Access | Times Cited: 4
Targeting Galectin-1 Overcomes Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma
Liting Zhou, Jie Tian, Keke Wang, et al.
Cancer Research (2024) Vol. 84, Iss. 22, pp. 3894-3908
Closed Access | Times Cited: 1
Leverage biomaterials to modulate immunity for type 1 diabetes
Zhangyan Jing, Yuan Li, Yumeng Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Galectin-1-mediated high NCAPG expression correlates with poor prognosis in gastric cancer
Tingrui Zheng, Qian Tao, Haihua Zhou, et al.
Aging (2023)
Open Access | Times Cited: 2
The regulatory role of mitotic catastrophe in hepatocellular carcinoma drug resistance mechanisms and its therapeutic potential
Jianwang Li, Xiaozhen Cheng, Denggao Huang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117598-117598
Open Access
MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters
Xinyan Lu, Hongxu Jin
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Investigation of the Effects of Galectin-1 on Enzalutamide Sensitivity and Cellular Functions in Prostate Cancer Cells and Its Clinical Diagnostic Value
Ya-Che Lee, Kai-Wu Yang, Ya-Yan Lai, et al.
Research Square (Research Square) (2024)
Closed Access
Page 1

Scroll to top